GLP-1 Medications, Diabetes and Weight Health

GLP-1 medications have reshaped how we think about type 2 diabetes and obesity.

GLP-1 medicines such as semaglutide and tirzepatide, now widely available in the UK, have transformed treatment. For people with type 2 diabetes and established cardiovascular risk, evidence from major clinical trials supports cardiovascular and renal benefits alongside meaningful weight loss. But something worth considering, are we treating the number on the scales, or are we supporting long-term metabolic health?

What GLP-1 medications do – and what they don’t

GLP-1 medications work by mimicking a natural gut hormone. They enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. This improves HbA1c and supports clinically meaningful weight loss in many people. For those with type 2 diabetes, this can be genuinely life-changing.

However, a 2026 review published in Diabetes.co.uk highlighted that informed use matters. The most common side effects are gastrointestinal and often manageable, but there are important edge cases around gallbladder disease, thyroid cancer risk in susceptible groups, and eye complications in certain individuals.

Weight loss is not the same as weight health

One of the most important shifts in this conversation is the distinction between losing weight and improving metabolic health. Patients can lose weight without improving their overall metabolic health. Weight on its own is a number – body composition, muscle mass, bone density, inflammatory markers, and metabolic function tell a far more complete story.

This matters particularly in the context of GLP-1 use. Addressing underlying metabolic drivers – rather than focusing on the number on the scales alone – helps ensure weight loss translates into lasting health improvements.

Reviews from the Institute for Functional Medicine (IFM) and broader clinical literature highlight that dietary patterns such Mediterranean, DASH, and low-carbohydrate patterns are associated with improved metabolic parameters. There is also evidence that combined aerobic and resistance training improves body composition, lipid and glucose metabolism, and physical function in people with type 2 diabetes.

In other words, medication is one tool. Supporting overall metabolic health – nutrition, movement, sleep, stress and the wider drivers of insulin resistance and inflammation – helps make weight loss meaningful for long-term wellbeing.

How functional medicine supports people with diabetes

More than four million people in the UK live with a diagnosis of type 2 diabetes, with an estimated further 1.3 million undiagnosed and over 6 million people at increased risk (Diabetes UK, 2024).

Dr Konrad Grosser is a consultant cardiologist and one of the very few interventional cardiologists in the UK certified by the Institute for Functional Medicine (IFM). His approach to diabetes goes beyond blood sugar management to examine the root causes of metabolic dysfunction, including connections with insulin resistance, inflammation, gut health, hormonal balance, and cardiovascular risk.

For patients already taking GLP-1 medication, this kind of integrative consultation can support a more comprehensive approach to long-term metabolic health, alongside, and not as a replacement for, the care of the prescribing clinician and GP.

This article is for general information and does not constitute medical advice.

Book a consultation with Dr Konrad Grosser at KentCardio to explore a personalised approach to your metabolic health: https://kentcardio.com/book/